OGEN Stock Overview
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Oragenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.08 |
| 52 Week High | US$7.74 |
| 52 Week Low | US$1.00 |
| Beta | 0.32 |
| 1 Month Change | -6.90% |
| 3 Month Change | -55.92% |
| 1 Year Change | -61.43% |
| 3 Year Change | -97.17% |
| 5 Year Change | -96.32% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| OGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.9% | 3.4% | 1.6% |
| 1Y | -61.4% | 3.8% | 25.1% |
Return vs Industry: OGEN underperformed the US Biotechs industry which returned 2.8% over the past year.
Return vs Market: OGEN underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| OGEN volatility | |
|---|---|
| OGEN Average Weekly Movement | 19.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OGEN's share price has been volatile over the past 3 months.
Volatility Over Time: OGEN's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 5 | Mike Redmond | www.oragenics.com |
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics.
Oragenics, Inc. Fundamentals Summary
| OGEN fundamental statistics | |
|---|---|
| Market cap | US$4.84m |
| Earnings (TTM) | -US$20.66m |
| Revenue (TTM) | US$37.65k |
128.5x
P/S Ratio-0.2x
P/E RatioIs OGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OGEN income statement (TTM) | |
|---|---|
| Revenue | US$37.65k |
| Cost of Revenue | US$15.49m |
| Gross Profit | -US$15.45m |
| Other Expenses | US$5.20m |
| Earnings | -US$20.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.61 |
| Gross Margin | -41,040.42% |
| Net Profit Margin | -54,858.14% |
| Debt/Equity Ratio | 9.9% |
How did OGEN perform over the long term?
See historical performance and comparison